Related Experiment Video

Updated: Dec 26, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.0K

A patent review of anticancer glucocorticoid receptor modulators (2014-present)

Marianna Lucafò1, Martina Franzin2, Giuliana Decorti1,3

  • 1Institute for Maternal and Child Health I.R.C.C.S. Burlo Garofolo, Trieste, Italy.

Expert Opinion on Therapeutic Patents
|March 10, 2020
PubMed

Insights

Selective glucocorticoid receptor modulators show promise in cancer therapy by separating therapeutic effects from side effects. However, limited recent patents and scarce clinical data necessitate further research for improved efficacy and safety.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Glucocorticoids are used in treating hematological and solid tumors but cause significant side effects and resistance.
  • Selective glucocorticoid receptor modulators (SGRMs) aim to separate therapeutic efficacy (transrepression) from side effects (transactivation).

Purpose of the Study:

  • To review patent applications from 2014 to present concerning SGRMs in cancer therapy.
  • To discuss the mechanism of action of these compounds.

Main Methods:

  • Literature review of patent applications.
  • Analysis of identified patents for novel molecules and methods of use.
  • Discussion of SGRM mechanisms.

Main Results:

  • A limited number of patents have been identified in the field of SGRMs for cancer therapy.
  • Patents primarily focus on new molecule identification or methods of use for existing compounds.
  • Biological and clinical data for most patented SGRMs are scarce.

Conclusions:

  • Further research, particularly clinical studies, is required to ascertain the potential of SGRMs to improve efficacy and therapeutic index in cancer treatment.
  • The limited patent activity suggests an underexplored area with potential for future development.
Keywords:
Glucocorticoidscancerglucocorticoid receptorsselective glucocorticoid receptor modulators

More Related Videos

Hydrogel Arrays Enable Increased Throughput for Screening Effects of Matrix Components and Therapeutics in 3D Tumor Models10:49

Hydrogel Arrays Enable Increased Throughput for Screening Effects of Matrix Components and Therapeutics in 3D Tumor Models

Published on: June 16, 2022

2.9K
Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis09:13

Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis

Published on: January 5, 2024

1.8K

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
148
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.4K
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
184
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
356